Creatine: Phosphocreatine Kinetics, DHT Elevation, and Neurological Benefits

The creatine kinase (CK) reaction — PCr + ADP ↔ Cr + ATP — operates at near-equilibrium under resting conditions (Keq ≈ 166) and is thermodynamically driven toward ATP regeneration during high-intensity effort. During maximal exercise, muscle phosphocreatine (PCr) stores are depleted within 8–10 seconds, coinciding with the characteristic performance plateau in explosive efforts. Oral creatine supplementation increases skeletal muscle total creatine (TCr) by 10–40% depending on baseline dietary creatine intake, with responders (typically omnivores with moderate baseline TCr) showing larger PCr resaturation. The functional consequence is a 10–30% improvement in peak power output during repeated sprint protocols and a 5–15% increase in maximum load across resistance training sets — effect sizes replicated across hundreds of controlled trials with high internal validity.

The van der Merwe et al. (2009, Journal of Strength and Conditioning Research) double-blind crossover RCT in Division I collegiate rugby players (n=20) remains the most cited evidence for creatine's androgenic effect. After a 7-day loading phase (25g/day) followed by 14-day maintenance (5g/day), DHT increased by 56% above baseline during loading and remained 40% elevated during maintenance relative to placebo. The testosterone:DHT ratio changed significantly, consistent with enhanced 5α-reductase type I/II activity. The proposed mechanism involves creatine's role in supporting cellular energy status (PCr/Cr ratio) in peripheral tissues including skin and liver, where 5α-reductase is primarily expressed — higher energy availability supporting higher enzymatic throughput. Testosterone itself did not change significantly, suggesting the effect is post-synthetic rather than upstream stimulation.

The brain consumes approximately 20% of the body's resting ATP, and creatine kinase is highly expressed in neurons, astrocytes, and oligodendrocytes. Creatine's cerebral energy buffering capacity is demonstrated by studies in creatine deficiency syndromes (AGAT/GAMT mutations) which produce severe cognitive impairment reversed by supplementation. In healthy adults, creatine supplementation (20g/day acute, 5g/day chronic) improves performance on working memory tasks (backward digit span: SMD +0.3), particularly under sleep deprivation and cognitive load. Mechanistically, creatine supports BDNF signaling through the AKT-mTOR pathway downstream of cellular energy sensing. Separately, creatine is a methyl group acceptor — its synthesis from guanidinoacetate consumes a significant fraction of the body's S-adenosylmethionine (SAM), and supplementation reduces the metabolic demand on SAM, potentially freeing methyl groups for dopamine synthesis, gene regulation, and myelin maintenance.

The pharmacokinetics of creatine absorption follow saturation kinetics: single doses above 10g are incompletely absorbed, with surplus excreted renally as creatinine. The loading protocol (20–25g/day in 4–5 divided doses for 5–7 days) achieves muscle TCr saturation within 7 days but increases GI side effects (osmotic diarrhea, cramping) and represents no long-term advantage over a maintenance-only protocol. At 5g/day maintenance, TCr saturation is achieved within 28 days and is pharmacologically equivalent. Creatine monohydrate remains the gold standard — buffered creatine (Kre-Alkalyn), creatine ethyl ester, and creatine HCl show no superiority in replicated trials and cost substantially more. Insulin potentiates creatine uptake via the creatine transporter (SLC6A8), making co-ingestion with carbohydrate or protein metabolically advantageous, particularly during the saturation phase.

The concern about creatine's renal safety originates from its conversion to creatinine, which elevates serum creatinine — a commonly used proxy for glomerular filtration rate (GFR). However, creatinine-based eGFR (CKD-EPI, MDRD equations) is invalidated as a renal function marker in creatine users due to this non-pathological elevation. Cystatin C-based GFR calculation, which is independent of muscle creatine metabolism, shows no change with supplementation. The IOC and ISSN have both reviewed the safety literature and concluded creatine monohydrate at 3–5g/day is safe for long-term use in healthy individuals. Published longitudinal data extends to 5 years of continuous supplementation (Greenhaff 2003, NSCA review) without adverse renal outcomes. The contraindication is pre-existing renal insufficiency, where the additional creatinine load may complicate monitoring.

Sarcopenic men over 40 lose approximately 1–2% of skeletal muscle mass per year absent specific countermeasures. The combination of creatine supplementation and resistance training is the most evidence-supported intervention for attenuating this loss. A 2017 Cochrane-level meta-analysis (Chilibeck et al.) of 22 RCTs found that older adults taking creatine alongside resistance training gained significantly more lean mass (mean +1.37 kg) and strength (mean +5–10% greater than training alone) versus resistance training without creatine. The proposed mechanisms include enhanced satellite cell activation, improved myofibrillar protein synthesis signaling via mTORC1, and mitochondrial biogenesis support. Given the relationship between lean mass, insulin sensitivity, testosterone, and all-cause mortality, creatine's utility in aging men extends substantially beyond athletic performance.